Cero Therapeutics Holdings, Inc. has taken a significant step in its business strategy by entering into a Stock Purchase Agreement with SRX Global Inc. The agreement, signed on October 6, 2026, involves the sale of Cero Therapeutics, Inc., its wholly owned subsidiary. This transaction is expected to reshape the company's structure and financial obligations, marking a pivotal moment in its operations.
The sale is particularly noteworthy as Cero Therapeutics operates within the biological products sector, specifically under the SIC code 2836, which covers biological products excluding diagnostic substances. This move could lead to shifts in competition within the industry as Cero navigates its new direction.
According to the filing, upon completion of the transaction, Cero Therapeutics will no longer own the subsidiary. The agreement includes a provision that extends the maturity date of a Consolidated Senior Secured Promissory Note entered into on August 27, 2026, to five business days following the earlier of the closing date or the valid termination of the Purchase Agreement.
At the closing of the transaction, Cero Therapeutics will receive shares of SRX common stock valued at $1,000,000, based on the lower of the closing price of SRX common stock or the 20-day volume-weighted average price. Additionally, the agreement includes the forgiveness of obligations under the Consolidated Note, which has an outstanding principal balance of approximately $8.25 million, along with the assumption of certain liabilities by SRX.
The Purchase Agreement also features a 30-day go-shop period, allowing Cero Therapeutics to solicit alternative acquisition proposals. This period is designed to encourage competitive offers, potentially leading to a more favorable outcome for the company. Cero has engaged Joseph Gunnar & Co., LLC to manage this go-shop process.
If Cero receives a superior proposal during this period, the agreement allows for an additional 45 days to negotiate that proposal. However, the agreement restricts further solicitation after the go-shop period unless a superior proposal is received.
The Purchase Agreement outlines specific termination rights and reciprocal termination fees, including a $750,000 fee payable by Cero if it accepts a superior proposal. SRX may also be liable for a similar fee under certain conditions. The closing of the transaction is contingent upon various conditions, including the acquisition of preferred stock and necessary waivers from preferred stockholders.
The Cero Therapeutics board, acting on the recommendation of a special committee, approved the Purchase Agreement, which is structured to eliminate and reduce the company’s secured debt. Notably, this transaction does not require a vote or consent from Cero's common stockholders under Delaware law.
As Cero Therapeutics moves forward with this transaction, the implications for its operations and the broader biological products industry remain to be seen. The go-shop period may yield additional offers, potentially altering the landscape of the company's future.